Trialect

Active

Therapeutic Catalyst

Cancer Research UK

The Therapeutic Catalyst accelerates the translation of laboratory discoveries into novel cancer therapeutics.

About

The Therapeutic Catalyst supports exploratory drug discovery efforts to validate and de-risk targets and technologies and position them for onward investment and progression. This provides you with the opportunity to take your research idea from bench to patients with a single funder and partner.

Funded projects run collaboratively between academic and Cancer Research Horizons drug discovery laboratories (Therapeutic Innovation), with joint decision-making and accountability for project progression.

At the proposal stage, you will be assigned a scientist from Therapeutic Innovation to support you throughout your project, working with you to build and pitch the proposal. These scientists bring significant expertise and serve as a single point of contact to manage all the internal (Cancer Research Horizons drug discovery) and external resources required to deliver your project.

We can also offer additional expertise, resources, and capabilities from across Cancer Research Horizons, Cancer Research UK, and our wider investigator network to help your project progress more effectively. Additionally, if appropriate, Cancer Research Horizons can support you in identifying and engaging with potential commercial partners or other options to accelerate the project toward patient benefit.

Scientific remit

This scheme aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering. We are seeking projects with strong therapeutic potential to deliver patient benefit.

We invite applications for early drug discovery proposals from across all cancer indications and modalities. Some examples of projects we might fund include the following areas:

Deconvolution and validation of novel targets and pathways
Novel therapeutic approaches to validated targets
Development of platforms, assays and screens to identify novel cancer therapeutics or targets
Drug discovery feasibility and progressing more advanced assets

Specialties

Cancer

Drug Development

Oncology

Drug Delivery

Immunology

Eligibility Requirements

Be an academic researcher based at any university or research institute world-wide
Have your own lab and/or have undertaken a significant period of postdoctoral research

This scheme is open to global applications.

Sponsor Details

Sponsor Institute/Organizations: Cancer Research UK

Address: 2 Redman Place, London, E20 1JQ

View Funding Opportunity

Grant

Letter Of Intent Deadline:

Oct 25, 2024

Final Deadline:

Oct 25, 2024

Funding Amount:

$250,000

5 awards available. Successful projects will receive up to £250k for up to 18 months.This funding covers resources externally from the applying academic laboratory and/or outsourced activities. Academic funding can be provided for staff time (research or technical) and any associated running expenses